- Home
- MGRX vs AYTU Comparison
MGRX vs AYTU Comparison
Compare MGRX & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- AYTU
- Stock Information
- Founded
- MGRX 2021
- AYTU N/A
- Country
- MGRX United States
- AYTU United States
- Employees
- MGRX N/A
- AYTU N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- MGRX Technology
- AYTU Health Care
- Exchange
- MGRX Nasdaq
- AYTU Nasdaq
- Market Cap
- MGRX 8.1M
- AYTU 9.6M
- IPO Year
- MGRX 2023
- AYTU N/A
- Fundamental
- Price
- MGRX $1.68
- AYTU $2.10
- Analyst Decision
- MGRX
- AYTU
- Analyst Count
- MGRX 0
- AYTU 0
- Target Price
- MGRX N/A
- AYTU N/A
- AVG Volume (30 Days)
- MGRX 189.8K
- AYTU 621.9K
- Earning Date
- MGRX 08-13-2025
- AYTU 05-14-2025
- Dividend Yield
- MGRX N/A
- AYTU N/A
- EPS Growth
- MGRX N/A
- AYTU N/A
- EPS
- MGRX N/A
- AYTU N/A
- Revenue
- MGRX $511,084.00
- AYTU $81,659,000.00
- Revenue This Year
- MGRX N/A
- AYTU N/A
- Revenue Next Year
- MGRX N/A
- AYTU $8.68
- P/E Ratio
- MGRX N/A
- AYTU N/A
- Revenue Growth
- MGRX N/A
- AYTU 0.41
- 52 Week Low
- MGRX $1.32
- AYTU $0.95
- 52 Week High
- MGRX $7.66
- AYTU $2.96
- Technical
- Relative Strength Index (RSI)
- MGRX 42.14
- AYTU 60.77
- Support Level
- MGRX $1.86
- AYTU $1.97
- Resistance Level
- MGRX $2.04
- AYTU $2.17
- Average True Range (ATR)
- MGRX 0.17
- AYTU 0.14
- MACD
- MGRX -0.03
- AYTU 0.00
- Stochastic Oscillator
- MGRX 0.00
- AYTU 58.33
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.